Bergen, Norway, 6 January 2022 - BerGenBio ASA (OSE:BGBIO) announces that an
extraordinary general meeting in the Company was held on 6 January 2022.
All proposals were resolved as presented in the notice convening the
extraordinary general meeting distributed on 16 December 2022, as further set
out in the minutes from the extraordinary general meeting attached hereto and
available at https://www.bergenbio.com/investors/general-
meetings/ (https://www.bergenbio.com/investors/general-%20meetings/)
-Ends-
For further information, please contact:
Martin Olin, CEO, BerGenBio ASA
ir@bergenbio.com
Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com
Forward looking statements
This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.
This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.